Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries.

Autor: Szilberhorn L; Syreon Research Institute, 1142, Budapest, Hungary., Zelei T; Syreon Research Institute, 1142, Budapest, Hungary., Vellekoop H; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Huygens S; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Versteegh M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Mölken MR; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Koleva-Kolarova R; Health Economics Research Centre, University of Oxford, OX3 7LF, Oxford, UK., Tsiachristas A; Health Economics Research Centre, University of Oxford, OX3 7LF, Oxford, UK., Wordsworth S; Health Economics Research Centre, University of Oxford, OX3 7LF, Oxford, UK., Nagy B; Syreon Research Institute, 1142, Budapest, Hungary.; Center for Health Technology Assessment, Semmelweis University, 1091, Budapest, Hungary.
Jazyk: angličtina
Zdroj: Personalized medicine [Per Med] 2023 Jul; Vol. 20 (4), pp. 387-399. Date of Electronic Publication: 2023 Sep 04.
DOI: 10.2217/pme-2023-0017
Abstrakt: Background: Correct diagnosis of maturity-onset diabetes of the young (MODY), which is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate treatment. Materials & Methods: A diabetes model was adapted to Hungary, the Netherlands, and the UK to analyse the cost-effectiveness and budget impact of different screening strategies for MODY with 20 years time horizon. Results: Compared with no screening, screening with the MODY calculator then genetic testing is considered cost-effective with respect to each country's willingness to pay threshold. The addition of autoantibody testing dominated the no screening strategy. The budget impact of the strategies ranges between 0.001 and 0.025% of annual public healthcare spending. Conclusion: The analysed strategies are considered good value for money with potential cost savings in the long term.
Databáze: MEDLINE
Externí odkaz: